Condition or disease | Intervention/treatment | Phase |
---|---|---|
Overactive Bladder Urinary Urge Incontinence Urgency-frequency Syndrome | Device: InterStim Basic Evaluation lead and foramen needle | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 110 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | To characterize proportion of subjects who demonstrate motor or sensory response(s) during lead placement using the InterStim Basic Evaluation Lead. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | InterStim Basic Evaluation Lead Post Market Clinical Follow-Up Study |
Actual Study Start Date : | November 28, 2019 |
Actual Primary Completion Date : | October 6, 2020 |
Actual Study Completion Date : | October 9, 2020 |
Arm | Intervention/treatment |
---|---|
Basic evaluation
Subjects with overactive bladder will go through InterStim basic evaluation with the commercially approved foramen needle and basic evaluation kit.
|
Device: InterStim Basic Evaluation lead and foramen needle
Commercial devices within their intended use as described in approved Instructions for Use.
|
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Florida | |
Pinellas Urology | |
Saint Petersburg, Florida, United States, 33710 | |
Florida Urology Partners | |
Tampa, Florida, United States, 33606 | |
United States, Minnesota | |
Minnesota Urology (Plymouth) | |
Plymouth, Minnesota, United States, 55441 | |
United States, New Jersey | |
Urologic Research and Consulting | |
Englewood, New Jersey, United States, 07631 | |
United States, North Carolina | |
FirstHealth Urogynecology | |
Hamlet, North Carolina, United States, 28345 | |
United States, Ohio | |
Wright State Physicians | |
Fairborn, Ohio, United States, 45234-2640 | |
United States, South Carolina | |
Prisma Health | |
Greenville, South Carolina, United States, 29605-4627 | |
Southern Urogynecology | |
West Columbia, South Carolina, United States, 29169-3456 | |
United States, Texas | |
Urology Partners of North Texas | |
Arlington, Texas, United States, 76017 | |
United States, Virginia | |
Urology of Virginia | |
Virginia Beach, Virginia, United States, 23642-1815 | |
Canada, Ontario | |
University Urology Associates | |
Toronto, Ontario, Canada, M5T 2S8 | |
Netherlands | |
Radboud UMC | |
Nijmegen, Netherlands, 6525 GA | |
United Kingdom | |
The Bristol Urological Institute | |
Bristol, United Kingdom, BS10 5NB | |
The Newcastle upon Tyne Hospitals | |
Newcastle Upon Tyne, United Kingdom, NE7 7DN | |
Salford Royal NHS Foundation Trust | |
Salford, United Kingdom, M68HD |
Study Director: | BASIC Clinical Research Study Team | Medtronic |
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | July 9, 2019 | ||||||
First Posted Date ICMJE | July 11, 2019 | ||||||
Last Update Posted Date | October 19, 2020 | ||||||
Actual Study Start Date ICMJE | November 28, 2019 | ||||||
Actual Primary Completion Date | October 6, 2020 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures ICMJE |
Motor or sensory response(s) during lead placement [ Time Frame: During lead implant ] To characterize the proportion of subjects who demonstrate motor or sensory response(s) during lead placement using the InterStim basic evaluation lead.
|
||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||
Change History | |||||||
Current Secondary Outcome Measures ICMJE | Not Provided | ||||||
Original Secondary Outcome Measures ICMJE | Not Provided | ||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||
Descriptive Information | |||||||
Brief Title ICMJE | InterStim Basic Evaluation Lead Post-Market Clinical Follow-up Study | ||||||
Official Title ICMJE | InterStim Basic Evaluation Lead Post Market Clinical Follow-Up Study | ||||||
Brief Summary | Post-market clinical follow-up for continued assessment of safety and performance of the InterStim basic evaluation lead and foramen needle(s) used during a therapy evaluation. | ||||||
Detailed Description | Not Provided | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Not Applicable | ||||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Intervention Model Description: To characterize proportion of subjects who demonstrate motor or sensory response(s) during lead placement using the InterStim Basic Evaluation Lead. Masking: None (Open Label)Primary Purpose: Treatment |
||||||
Condition ICMJE |
|
||||||
Intervention ICMJE | Device: InterStim Basic Evaluation lead and foramen needle
Commercial devices within their intended use as described in approved Instructions for Use.
|
||||||
Study Arms ICMJE | Basic evaluation
Subjects with overactive bladder will go through InterStim basic evaluation with the commercially approved foramen needle and basic evaluation kit.
Intervention: Device: InterStim Basic Evaluation lead and foramen needle
|
||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Completed | ||||||
Actual Enrollment ICMJE |
110 | ||||||
Original Estimated Enrollment ICMJE |
100 | ||||||
Actual Study Completion Date ICMJE | October 9, 2020 | ||||||
Actual Primary Completion Date | October 6, 2020 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||||
Sex/Gender ICMJE |
|
||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | Canada, Netherlands, United Kingdom, United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT04016324 | ||||||
Other Study ID Numbers ICMJE | MDT19002 | ||||||
Has Data Monitoring Committee | No | ||||||
U.S. FDA-regulated Product |
|
||||||
IPD Sharing Statement ICMJE |
|
||||||
Responsible Party | MedtronicNeuro | ||||||
Study Sponsor ICMJE | MedtronicNeuro | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE |
|
||||||
PRS Account | MedtronicNeuro | ||||||
Verification Date | October 2020 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |